SEC Tracker
Get the app

Repligen RGEN

Repligen issues new convertible notes

Item 3.02 Unregistered share sale, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 issued
  2. Approximately $541.4 million in New Notes issued in exchange for $456.8 million in 2028 Notes
  3. Approximately $458.6 million in New Notes issued for cash
  4. Company plans to use $120 million of proceeds to repurchase shares at $188.64 per share

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025